Immune reconstitution after CD7 CAR ‐T cell therapy for refractory/relapsed acute T‐lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T‐ ALL / LBL )
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70201 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Xian Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD7, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
CD7 Chimeric Antigen Receptor‐T cell (CAR‐T) therapy demonstrates efficacy in relapsed/refractory (R/R) acute T‐lymphoblastic leukaemia (ALL)T‐ALL/lymphoblastic lymphoma (LBL), but concerns about T‐cell depletion and severe immunodeficiency persist. We compared infection rates and immune cell subsets in 60 R/R T‐ALL/LBL patients receiving naturally selected CD7 CAR‐T (NS7CAR‐T) with 60 R/R B‐ALL patients undergoing CD19 CAR‐T. Infections were monitored from infusion until allogeneic haematopoietic stem cell transplantation (HSCT) or up to 3 months. Overall infection rates did not significantly differ between groups (36.67% vs. 24.56%, p = 0.24), although the incidence of early immune effector cell‐associated haematotoxicity (ICAHT) grade III–IV was higher in the CD7 CAR‐T group than in the CD19 CAR‐T group (33.9% vs. 16.7%, p = 0.03). Post‐CD7 CAR‐T infusion analysis showed a significant decline in CD7(+) T cells and an increase in non‐CAR‐T‐derived CD7(−) T cells, particularly non‐CAR‐T cells, which rose to a median proportion of 84.4% (range: 22.1%–99.9%) by day 28; meanwhile, CD7(−) natural killer (NK) cells approached nearly 100% following the depletion of CD7(+) NK cells. This study indicates that while CD7 CAR‐T therapy significantly reduces CD7(+) T cells, it does not lead to increased short‐term infection rates. The notable expansion of non‐CAR‐T‐derived CD7(−) T and NK cells helps preserve immune function, highlighting distinct therapeutic mechanisms between CD7 CAR‐T and CD19 CAR‐T due to their different lineage restrictions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China.
- Lu Daopei Institute of Hematology, Beijing, China.
- Hebei Senlang Biotechnology Co., Ltd., Shijiazhuang, China.
ORCID-Profile: Xian Zhang
Zitieren
APA
Zhang, X., Wang, L., Kuang, N., Yang, J., Wang, H., Qiu, L., Wang, D., Sun, J., Long, J., & Lu, P. (2026). Immune reconstitution after CD7 CAR ‐T cell therapy for refractory/relapsed acute T‐lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T‐ ALL / LBL ). British Journal of Haematology. https://doi.org/10.1111/bjh.70201
Vancouver
Zhang X, Wang L, Kuang N, Yang J, Wang H, Qiu L, et al. Immune reconstitution after CD7 CAR ‐T cell therapy for refractory/relapsed acute T‐lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T‐ ALL / LBL ). British Journal of Haematology. 2026. doi:10.1111/bjh.70201
BibTeX
@article{Zhang2026,
author = {Zhang, Xian and Wang, Lin and Kuang, Na and Yang, Junfang and Wang, Hui and Qiu, Liyuan and Wang, Dongchu and Sun, Jian and Long, Jing and Lu, Peihua},
title = {Immune reconstitution after CD7 CAR ‐T cell therapy for refractory/relapsed acute T‐lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T‐ ALL / LBL )},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70201}
}
EUVIMED